Bank of India Mid Cap Fund
The scheme is to generate long-term capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Growthvine rating: 1/5 — ranked #29 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹10.10 (as of 2026-10-01) |
|---|
| AUM | ₹767 Cr |
|---|
| Expense ratio | 2.02% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −12.91% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 74.1% of NIFTY Midcap 150's upside and — of its downside.
Market cap allocation
| Large cap | 7.1% |
|---|
| Mid cap | 71.5% |
|---|
| Small cap | 21.4% |
|---|
Concentration
| Top 5 holdings | 22.3% |
|---|
| Top 10 holdings | 36.6% |
|---|
| Total holdings | 56 |
|---|
| Index overlap | 27.9% |
|---|
| Active share | 72.1% |
|---|
Top holdings
- Aurobindo Pharma Ltd. — 5.6%
- Multi Commodity Exchange of India Ltd — 4.9%
- Abbott India Ltd. — 4.4%
- Bharti Hexacom Limited — 4.1%
- One 97 Communications Limited — 3.4%
- QUALITY POWER ELECTRICAL EQUIPMENTS LIMITED — 3.1%
- UNO Minda Limited — 2.9%
- NIPPON LIFE INDIA ASSET MANAGEMENT LIMITED — 2.9%
- Mankind Pharma Limited — 2.7%
- Bank of maharashtra — 2.7%
Top sectors
- Banking & Financial — 16.3%
- Pharma & Biotech — 15.1%
- Electricals — 7.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 3.1% | Q1 (Top) | #7 of 31 |